Sentinus LLC
CAI icon

Sentinus LLC’s Caris Life Sciences CAI Stock Holding History

Sentinus LLC’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$249K Buy
+8,132
New +$183K 0.02% 611

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
J. H. Whitney Equity Partners VI
J. H. Whitney Equity Partners VI New Canaan, Connecticut $53.6M AUM 1.26% 1-Year Est. Return

Sentinus LLC's CAI Position: Q3 2026 in Review

Sentinus LLC opened a new position in Caris Life Sciences (CAI) in Q3 2026: 8,132 shares worth $249K. The stake represents 0.02% of the portfolio and ranks #611 among its holdings.

210 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

  • Sentinus LLC held 8,132 shares of Caris Life Sciences worth $249K as of Q3 2026.
  • Caris Life Sciences was a new Sentinus LLC position in Q3 2026.
  • Caris Life Sciences made up 0.02% of Sentinus LLC's portfolio in Q3 2026, its #611 holding.
  • 210 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on Sentinus LLC's 13F filing for Q3 2026, filed 12 Nov 2026.